Heart drug combo under microscope: will it help or harm?

NCT ID NCT07431294

Not yet recruiting Disease control Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 30, 2026 · Updated 3 times

Summary

This early-stage study tests whether it is safe to take nitroglycerin spray (used for chest pain) together with an experimental drug called nurandociguat (designed to help kidneys) in 36 adults with stable coronary artery disease. Both drugs widen blood vessels, so the main concern is a sudden drop in blood pressure. The study will monitor side effects and how the drugs interact in the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Nitroglycerin spray and nurandociguat
What this could lead to: If successful, this could show that combining nitroglycerin with nurandociguat is safe, potentially leading to better treatment options for people with both heart and kidney disease.
What could go wrong: This is a very early Phase 1 safety study with only 36 participants. It is not designed to prove effectiveness, and the combination may cause low blood pressure or other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STABLE CORONARY ARTERY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

STABLE CORONARY ARTERY DISEASE

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Comac Medical | Phase I Clinical Research Unit

Sofia, Sofia City Province, 1000, Bulgaria
SocraTec R&D Erfurt-Clinical Pharmacology Unit

Erfurt, Thuringia, 99084, Germany
UK Bonn Institut für Klinische Chemie und Klinische Pharmakologie, Phase I Einheit und Arzneimitteltherapiesicherheit

Bonn, North Rhine-Westphalia, 53127, Germany
Universitätsklinikum Heidelberg - Zentrum für Innere Medizin, Abteilung Klinische Pharmakologie und Pharmakoepidemologie

Heidelberg, Baden-Wurttemberg, 69120, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.